Neutrophil - Lymphocyte ratio as a predictive marker for Early Stage Diabetic Nephropathy

Background: Diabetic nephropathy is a diabetic microvascular complication. An increase in urine albumin excretion isthe clinical manifestation. Total white blood cell count is a basic but sensitive measure of inflammation that has beenevaluated as an inflammatory marker in a variety of cardiac and noncardiac ailments such as stroke, acute myocardialinfarction , and heart failure.Objective: To analyze Neutrophil-lymphocyte ratio as a predictive marker for early stage diabetic retinopathy.Methods: The research enrolled 230 individuals, with 115 of them having type 2 diabetes and 69 having Early Stage DN.The control group consisted of 115 healthy volunteers of similar age and gender. All of the patients’ samples was collectedand tested for HBA1c, CBC, FBS, PPBS, RFT, Urine microalbumin, and Urine albumin creatinine ratio. The Mogensen DNdiagnostic criteria and the American Diabetes Association was usedResults: This research had a total of 230 participants. Diabetic nephropathy patients and non-diabetic nephropathy patientswere divided into two groups. NLR was shown to have a substantial relationship with neutrophil and lymphocyte counts.In the DN group, mean neutrophil counts increased while mean lymphocyte levels decreased, resulting in a substantiallyhigher NLR value in the patient group than in the control group. The patient group’s mean NLR values were considerablyhigher than the control group’s (P 0001), and the NLR values of patients with early stage DN were significantly higherthan those of patients without early stage DN (P 0001). The results reveal that DN was associated with NLR, Creatinine,and Insulin Resistance.Conclusion: NLR might be used as a predictor and predictive risk factor for early-stage diabetic nephropathy. This testis affordable, routinely performed, and easy to compute. NLR can be a cost-effective alternative marker as a predictor ofDiabetic Nephropathy in a setting with constrained laboratory resources.